Biodel sinks 30% as BIOD-123 proves non-inferior to Humalog
This article was originally published in Scrip
Executive Summary
Biodel's rapid-acting mealtime insulin BIOD-123 met the Phase II primary endpoint of non-inferiority to Humalog (lispro) in the treatment of type 1 diabetes, but the company's stock price sank 29.8% on 9 September based on data that show its product candidate may be less tolerable than Lilly's rapid-acting mealtime insulin analog.